Q32 Bio Inc. (LON:0T6G)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 203.31M +871.0% |
| Revenue (ttm) | 40.48M |
| Net Income | 24.29M |
| EPS | 1.18 |
| Shares Out | n/a |
| PE Ratio | 5.92 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,621 |
| Open | 9.70 |
| Previous Close | 9.62 |
| Day's Range | 9.24 - 9.73 |
| 52-Week Range | 1.93 - 23.50 |
| Beta | -0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Mar 10, 2027 |
About Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatm... [Read more]
News
Q32 Bio Earnings release: Q3 2026
Q32 Bio released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Q32 Bio Quarterly report: Q3 2026
Q32 Bio has published its Q3 2026 quarterly earnings report on November 4, 2026.
Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
-- Presented additional 36-week results and 16-week off-drug findings from Part B of the SIGNAL-AA clinical trial of bempikibart in late-breaking oral and poster presentations at EADV Congress 2026; d...
Q32 Bio Slides: Corporate presentation
Q32 Bio has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Q32 Bio management to meet with Cantor Fitzgerald
Meetings to be held in Denver October 20-21 hosted by Cantor Fitzgerald.
Q32 Bio initiated with an Outperform at Leerink
Leerink analyst Will Soghikian initiated coverage of Q32 Bio (QTTB) with an Outperform rating and $40 price target The firm believes Q32 Bio offers pure play on a late-stage biologic…
Q32 Bio Inc trading halted, volatility trading pause
09:30 EDT Q32 Bio (QTTB) Inc trading halted, volatility trading pause
Q32 Bio anncounces results from Part B of the SIGNAL-AA Phase 2a clinical trial
Q32 Bio (QTTB) announced additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with…
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
-- Clinically meaningful efficacy data observed on primary and key secondary endpoints at Week 36 -- -- Robust durability, including maintenance and deepening of response, observed following the 16-we...
Q32 Bio initiated with a Buy at Clear Street
Clear Street initiated coverage of Q32 Bio (QTTB) with a Buy rating and $38 price target The firm has “strong conviction” in bempikibart’s path to a competitive severe alopecia areata…
Q32 Bio initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft initiated coverage of Q32 Bio (QTTB) with a Buy rating and $29 price target Q32 “remains mispriced” compared to its potential blockbuster opportunity in severe/very se...
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026
-- Late-breaking oral and poster presentations to feature additional 36-week results and initial findings from the 16-week off-drug period from Part B of the SIGNAL-AA clinical trial of bempikibart in...
Q32 Bio Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The session highlighted strong phase II results for bempikibart in alopecia areata, with robust efficacy, durable responses, and a favorable safety profile. The addressable U.S. market is estimated at $5 billion, with biologics expected to become the preferred treatment. Phase III is fully funded and will leverage phase II learnings.
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D.
-- Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage clinical development -- -- Dr. Hershberger is a drug developmen...
Q32 Bio Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Bempikibart demonstrated strong efficacy and safety in alopecia areata, with a multibillion-dollar U.S. market opportunity and low current biologic penetration. Phase III is planned as a single pivotal study, with key data and regulatory milestones expected over the next year.
Q32 Bio Transcript: Wells Fargo 21st Annual Healthcare Conference
Positive phase II data for bempikibart in alopecia areata show JAK-like efficacy and a strong safety profile, with plans to advance to phase III and explore additional indications. Upcoming milestones include new data releases, regulatory guidance, and pipeline expansion decisions.
Q32 Bio to Participate in Upcoming September Investor Conferences
WALTHAM, Mass., Sept. 1, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and ...
Q32 Bio initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Q32 Bio (QTTB) with an Overweight rating and $34 price target Q32 is a clinical-stage immunology company developing bempikibart for severe or very severe alopecia…
Q32 Bio Quarterly report: Q2 2026
Q32 Bio has published its Q2 2026 quarterly earnings report on August 5, 2026.
Q32 Bio Earnings release: Q2 2026
Q32 Bio released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Q32 Bio Slides: Corporate presentation
Q32 Bio has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
-- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented at a...
Q32 Bio price target raised to $36 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Q32 Bio (QTTB) to $36 from $13 and keeps a Buy rating on the shares. The firm says the positive week 36…
Q32 Bio files to sell 6.88M shares of common stock for holders
16:15 EDT Q32 Bio (QTTB) files to sell 6.88M shares of common stock for holders